Research

Assessing drug distribution in tissues expressing P-glycoprotein through physiologically based pharmacokinetic modeling: model structure and parameters determination

Frédérique Fenneteau¹ , Jacques Turgeon¹ , Lucie Couture^1,2 , Véronique Michaud¹ , Jun Li^3,4 and Fahima Nekka^1,3

¹  Faculté de Pharmacie, Université de Montréal, Montréal, Québec, Canada

²  Charles River Laboratories Preclinical Services Montréal Inc., Montréal, Québec, Canada

³  Centre de Recherche Mathématiques, Université de Montréal, Montréal, Québec, Canada

⁴  Pharsight, Montréal, Québec, Canada

author email corresponding author email

Theoretical Biology and Medical Modelling 2009, 6:2doi:10.1186/1742-4682-6-2

Published:	15 January 2009

Abstract

Background

The expression and activity of P-glycoproteins due to genetic or environmental factors may have a significant impact on drug disposition, drug effectiveness or drug toxicity. Hence, characterization of drug disposition over a wide range of conditions of these membrane transporters activities is required to better characterize drug pharmacokinetics and pharmacodynamics. This work aims to improve our understanding of the impact of P-gp activity modulation on tissue distribution of P-gp substrate.

Methods

A PBPK model was developed in order to examine activity and expression of P-gp transporters in mouse brain and heart. Drug distribution in these tissues was first represented by a well-stirred (WS) model and then refined by a mechanistic transport-based (MTB) model that includes P-gp mediated transport of the drug. To estimate transport-related parameters, we developed an original three-step procedure that allowed extrapolation of in vitro measurements of drug permeability to the in vivo situation. The model simulations were compared to a limited set of data in order to assess the model ability to reproduce the important information of drug distributions in the considered tissues.

Results

This PBPK model brings insights into the mechanism of drug distribution in non eliminating tissues expressing P-gp. The MTB model accounts for the main transport mechanisms involved in drug distribution in heart and brain. It points out to the protective role of P-gp at the blood-brain barrier and represents thus a noticeable improvement over the WS model.

Conclusion

Being built prior to in vivo data, this approach brings an interesting alternative to fitting procedures, and could be adapted to different drugs and transporters.

The physiological based model is novel and unique and brought effective information on drug transporters.